Serum potassium and adverse outcomes across the range of kidney function: A CKD Prognosis Consortium meta-analysis

European Heart Journal

Volumn 39, Issue 17, 2018, Pages 1535-1542

  Kovesdy, Csaba P ^a,b   Matsushita, Kunihiro ^c   Sang, Yingying ^c   Brunskill, Nigel J ^d,e   Carrero, Juan J ^f   Chodick, Gabriel ^g,h   Hasegawa, Takeshi ^i,j,k,l   Heerspink, Hiddo L ^m   Hirayama, Atsushi ⁿ   Landman, Gijs W D ^o   Levin, Adeera ^p,q   Nitsch, Dorothea ^r   Wheeler, David C ^s   Coresh, Josef ^c   Hallan, Stein I ^t,u   Shalev, Varda ^g,h   Grams, Morgan E ^c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

^g MACCABI HEALTHCARE SERVICES   (Israel)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ SHOWA UNIVERSITY   (Japan)

^j SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^k FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^l KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ YAMAGATA UNIVERSITY   (Japan)

^o ISALA HOSPITAL   (Netherlands)

^p BC Provincial Renal Agency   (Canada)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^s UNIVERSITY COLLEGE LONDON   (United Kingdom)

^t NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^u TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Albuminuria; End stage renal disease; Estimated glomerular filtration rate; Mortality; Potassium

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADVERSE OUTCOME; ALBUMINURIA; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE SEVERITY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KIDNEY FUNCTION; OUTCOME ASSESSMENT; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; ADULT; AGED; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMORBIDITY; GLOMERULUS FILTRATION RATE; META ANALYSIS; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY;

ADULT; AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPOKALEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85052306596     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehy100     Document Type: Article

References (55)

1. Dittrich KL, Walls RM. Hyperkalemia: eCG manifestations and clinical considerations. J Emerg Med 1986;4:449–455.
2. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J 2006;33:40–47.
3. Priori SG, Blomstrom-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J 2015; 36:2757–2759.
4. Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012;60:310–315.
5. Bourgoignie JJ, Kaplan M, Pincus J, Gavellas G, Rabinovitch A. Renal handling of potassium in dogs with chronic renal insufficiency. Kidney Int 1981;20: 482–490.
6. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol 2014;10:653–662.
7. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012;7:1234–1241.
8. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 2012;120: c8–16.
9. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585–592.
10. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009;169:1156–1162.
11. Fleet JL, Shariff SZ, Gandhi S, Weir MA, Jain AK, Garg AX. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open 2012;2:e002011.
12. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007;298: 2038–2047.
13. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015;88:950–957.
14. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
15. Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K, Kinjo K, Shiohira Y, Fukiyama K. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis 1996;28:541–548.
16. Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, Kopple JD, Kalantar-Zadeh K. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007;2:999–1007.
17. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. Jama 2012;307:157–164.
18. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010;5:762–769.
19. Epstein FH, Signs and symptoms of electrolyte disorders. In: MH Maxwell, CR Kleeman (eds). Clinical Disorders of Fluid and Electrolyte Metabolism. 3rd ed. New York: McGraw-Hill; 1980. p499–516.
20. Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, Naimark D, Oien C, Smith DH, Coresh J, Sarnak MJ, Stengel B, Tonelli M, Tonelli M, Hemmelgarn BR, James MT, Turin TC, Coresh J, Matsushita K, Grams M, Sang Y, Shlipak M, Sarnak MJ, Katz R, Wheeler DC, Emberson J, Landray MJ, Townend JN, Green J, Kirchner HL, Perkins R, Chang AR, Romundstad S, Aasarød K, Øien CM, Hallan S, Smith DH, Thorp ML, Johnson ES, Chodick G, Herzel E, Katz R, Shalev V, Gansevoort RT, Bakker SJL, Lambers Heerspink HJ, van der Harst P, Jee SH, Kimm H, Mok Y, Tangri N, Naimark D, Ärnlöv J, Larsson A, Lannfelt L, Kovesdy CP, Kalantar-Zadeh K, Coresh J, Grams M, Matsushita K, Gansevoort RT, de Jong PE, Iseki K, Levey AS, Sarnak MJ, Stengel B, Warnock D, Woodward M, Ballew SH, Coresh J, Grams M, Matsushita K, Sang Y, Woodward M. A meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis 2015;66: 591–601.
21. Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, Chow EK, Kasiske BL, Kovesdy CP, Nadkarni GN, Shalev V, Segev DL, Coresh J, Lentine KL, Garg AX; for the Chronic Kidney Disease Prognosis Consortium. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med 2016;374: 411–421.
22. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, Chodick G, Collins AJ, Djurdjev O, Elley CR, Evans M, Garg AX, Hallan SI, Inker LA, Ito S, Jee SH, Kovesdy CP, Kronenberg F, Heerspink HJ, Marks A, Nadkarni GN, Navaneethan SD, Nelson RG, Titze S, Sarnak MJ, Stengel B, Woodward M, Iseki K. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 2016;315:164–174.
23. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS, Prognosis Consortium CKD. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014;311:2518–2531.
24. Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DM, Nally J, Rothenbacher D, Stengel B, Iseki K, Matsushita K, Levey AS; the CKD Prognosis Consortium. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol 2016;27:2447–2455.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–612.
26. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766–772.
27. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, Itoh Y, Lieske JC, Seccombe DW, Jones G, Bunk DM, Curhan GC, Narva AS. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55:24–38.
28. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansevoort RT, Levey AS, Warnock DG, Sarnak MJ, Tonelli M, Hemmelgarn BR, James MT, Turin TC, Coresh J, Matsushita K, Grams M, Sang Y, Shlipak M, Sarnak MJ, Katz R, Wheeler DC, Emberson J, Landray MJ, Townend JN, Green J, Kirchner HL, Perkins R, Chang AR, Romundstad S, Aasarød K, Øien CM, Hallan S, Smith DH, Thorp ML, Johnson ES, Chodick G, Herzel E, Katz R, Shalev V, Gansevoort RT, Bakker SJL, Lambers Heerspink HJ, van der Harst P, Jee SH, Kimm H, Mok Y, Tangri N, Naimark D, Ärnlöv J, Larsson A, Lannfelt L, Kovesdy CP, Kalantar-Zadeh K, Coresh J, Grams M, Matsushita K, Gansevoort RT, de Jong PE, Iseki K, Levey AS, Sarnak MJ, Stengel B, Warnock D, Woodward M, Ballew SH, Coresh J, Grams M, Matsushita K, Sang Y, Woodward M. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis 2015;66:602–612.
29. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012;308:2349–2360.
30. Kovesdy CP. Updates in hyperkalemia: outcomes and therapeutic strategies. Rev Endocr Metab Disord 2017;18:41–47.
31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18: 891–975.
32. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
33. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients Study I. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004;27:21–30.
34. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
35. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P; the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939–945.
36. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857–1863.
37. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131–140.
38. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211–214.
39. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845–849.
40. Miao Y, Dobre D, Heerspink HJ, Brenner BM, Cooper ME, Parving HH, Shahinfar S, Grobbee D, de Zeeuw D. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 2011;54:44–50.
41. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ; on behalf of the PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32: 820–828.
42. Buysse JM, Huang IZ, Pitt B. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 2012;8:17–28.
43. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; for the OPAL-HK Investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015;372:211–221.
44. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014;312:2223–2233.
45. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015;372:222–231.
46. Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J Med 2015;128:1281–1287.
47. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, De BG, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck BC, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos
48. C, Xuereb RG. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035–3087.
49. Kovesdy CP, Appel LJ, Grams ME, Gutekunst L, McCullough PA, Palmer BF, Pitt B, Sica DA, Townsend RR. Potassium homeostasis in health and disease: a scientific workshop cosponsored by the National Kidney Foundation and the American Society Of Hypertension. Am J Kidney Dis 2017;11:783–800.
50. Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV, Jr, Navaneethan SD. Serum potassium, end-stage renal disease and mortality in chronic kidney disease. Am J Nephrol 2015;41:456–463.
51. Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol 2014;21:299–309.
52. Cremer W, Bock KD. Symptoms and course of chronic hypokalemic nephropathy in man. Clin Nephrol 1977;7:112–119.
53. Elger M, Bankir L, Kriz W. Morphometric analysis of kidney hypertrophy in rats after chronic potassium depletion. Am J Physiol 1992;262:F656–F667.
54. Riemenschneider T, Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol 1983;19:271–279.
55. Torres VE, Young WF Jr., Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med 1990;322:345–351.